Inhibikase Therapeutics Investor Relations Material
Latest events
Q2 2024
Inhibikase Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Inhibikase Therapeutics Inc
Access all reports
Inhibikase Therapeutics Inc. is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases and cancers. The company’s research primarily targets diseases related to protein misfolding, such as Parkinson's disease, by aiming to inhibit the malfunction of key cellular processes. Inhibikase Therapeutics develops therapeutics that aim to modify the progression of these diseases and improve patient outcomes. Its approach includes addressing both neurological and oncological conditions through small-molecule therapeutics. The company is headquartered in Atlanta, Georgia, and its shares are listed on the NASDAQ.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
IKT
Country
🇺🇸 United States